Randomized trial of statin administration for myocardial injury - Is intensive lipid-lowering more beneficial than moderate lipid-lowering before percutaneous coronary intervention?

被引:19
作者
Kinoshita, Masayoshi
Matsumura, Shin-ichirou
Sueyoshi, Kouichirou
Ogawa, Satoshi
Fukuda, Keiichi
机构
[1] Keio Univ, Sch Med, Div Regenerat Med & Adv Cardiac Therapeut, Shinjuku Ku, Tokyo 1608582, Japan
[2] Keio Univ, Sch Med, Dept Internal Med, Div Cardiol, Tokyo 108, Japan
[3] Shizuoka Municipal Shimizu Hosp, Div Cardiol, Shizuoka, Japan
关键词
angioplasty; cholesterol; stents;
D O I
10.1253/circj.71.1225
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Minor myocardial damage after percutaneous coronary intervention (PCI) is associated with cardiac risks, which statins seem to reduce. The aim of this study was to examine whether intensive lipid-lowering therapy is more effective in decreasing the risk of cardiac injury after PCI than moderate lipid-lowering therapy. Methods and Results Subjects comprised 42 patients with stable angina without previous statin treatment, randomly assigned to either an intensive lipid-lowering group (Group A: target low-density lipoprotein-cholesterol (LDL-C) < 70mg/dl) or a moderate lipid-lowering group (Group B: target LDL-C < 100mg/dl) 2 weeks before PCI. All patients took statins to reach target LDL-C levels. Incidence of periprocedural myocardial injury was assessed by analyzing levels of creatine kinase myocardial isozyme (CK-MB) and cardiac troponin T (TnT) before and 6, 12 and 24 It after PCI. Minor myocardial damage was defined as TnT elevation to > 0.01 ng/ml. Frequency of minor myocardial damage was 14.2% in Group A and 47.6% in Group B (p=0.043). CK-MB was above the upper limit of normal (ULN) in 19% of Group A and 33.3% of Group B (p=0.44), and CK-MB was >3 x ULN in 9.5% of Group A and 19% of Group B (p=0.66). Conclusions Intensive lipid-lowering therapy before PCI reduces minor myocardial damage during PCI with stenting compared with moderate lipid-lowering therapy.
引用
收藏
页码:1225 / 1228
页数:4
相关论文
共 29 条
  • [21] Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial
    Koopal, Charlotte
    Marais, A. David
    Westerink, Jan
    van der Graaf, Yolanda
    Visseren, Frank L. J.
    JOURNAL OF LIPID RESEARCH, 2017, 58 (11) : 2180 - 2187
  • [22] Echolucency of carotid plaque is useful for selecting high-risk patients with chronic coronary artery disease who benefit from intensive lipid-lowering therapy
    Uematsu, Manabu
    Nakamura, Takamitsu
    Horikoshi, Takeo
    Yoshizaki, Toru
    Watanabe, Yosuke
    Kobayashi, Tsuyoshi
    Saito, Yukio
    Nakamura, Kazuto
    Obata, Jun-Ei
    Kugiyama, Kiyotaka
    JOURNAL OF CARDIOLOGY, 2021, 77 (06) : 590 - 598
  • [23] Lipid-lowering, antihypertensive, and antithrombotic effects of nattokinase combined with red yeast rice in patients with stable coronary artery disease: a randomized, double-blinded, placebo-controlled trial
    Liu, Man
    Xu, Ziyi
    Wang, Zongling
    Wang, Di
    Yang, Mingzhe
    Li, Hui
    Zhang, Wei
    He, Ruikun
    Cheng, Huimin
    Guo, Peiyu
    Li, Zhongxia
    Liang, Hui
    FRONTIERS IN NUTRITION, 2024, 11
  • [24] Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent
    Ito, Tsuyoshi
    Fujita, Hiroshi
    Tani, Tomomitsu
    Ohte, Nobuyuki
    ATHEROSCLEROSIS, 2015, 239 (02) : 311 - 317
  • [25] Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA)
    Flueckiger, Peter
    Qureshi, Waqas
    Michos, Erin D.
    Blaha, Michael
    Burke, Gregory
    Sandfort, Veit
    Herrington, David
    Yeboah, Joseph
    CLINICAL CARDIOLOGY, 2017, 40 (03) : 163 - 169
  • [26] Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: Analysis of data from the MEGA Study, a large randomized controlled trial
    Uchiyama, Shinichiro
    Nakaya, Noriaki
    Mizuno, Kyoichi
    Ohashi, Yasuo
    Tajima, Naoko
    Kushiro, Toshio
    Teramoto, Tamio
    Nakamura, Haruo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 284 (1-2) : 72 - 76
  • [27] Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and pravastatin or atorvastatin evaluation and infection therapy - Thrombolysis in myocardial infarction 22 trials)
    Murphy, Sabina A.
    Cannon, Christopher P.
    Wiviott, Stephen D.
    de Lemos, James A.
    Blazing, Michael A.
    McCabe, Carolyn H.
    Califf, Robert M.
    Braunwald, Eugene
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (07) : 1047 - 1051
  • [28] Evaluation of C-Reactive Protein Before and On-Treatment as a Predictor of Benefit of Atorvastatin A Cohort Analysis From the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm
    Sever, Peter S.
    Poulter, Neil R.
    Chang, Choon L.
    Thom, Simon A. M.
    Hughes, Alun D.
    Welsh, Paul
    Sattar, Naveed
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (08) : 717 - 729
  • [29] Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22/reversal of atherosclerosis with aggressive lipid lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada
    Austin, PC
    Mamdani, MM
    CIRCULATION, 2005, 112 (09) : 1296 - 1300